These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 9504151

  • 1. Genetic therapy for transplant vascular sclerosis.
    Bennett CF, Stepkowski SM.
    Transpl Immunol; 1997 Dec; 5(4):299-302. PubMed ID: 9504151
    [No Abstract] [Full Text] [Related]

  • 2. Tackling the real culprits in Crohn's disease.
    Bonn D.
    Lancet; 1998 Jun 06; 351(9117):1710. PubMed ID: 9734899
    [No Abstract] [Full Text] [Related]

  • 3. Cationic lipid is not required for uptake and selective inhibitory activity of ICAM-1 phosphorothioate antisense oligonucleotides in keratinocytes.
    Nestle FO, Mitra RS, Bennett CF, Chan H, Nickoloff BJ.
    J Invest Dermatol; 1994 Oct 06; 103(4):569-75. PubMed ID: 7930684
    [Abstract] [Full Text] [Related]

  • 4. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease.
    Yacyshyn BR, Bowen-Yacyshyn MB, Jewell L, Tami JA, Bennett CF, Kisner DL, Shanahan WR.
    Gastroenterology; 1998 Jun 06; 114(6):1133-42. PubMed ID: 9609749
    [Abstract] [Full Text] [Related]

  • 5. ISIS 2302. Oligo-TCS.
    Drugs R D; 1999 Mar 06; 1(3):265-7. PubMed ID: 10566042
    [No Abstract] [Full Text] [Related]

  • 6. An overview of progress in antisense therapeutics.
    Crooke ST.
    Antisense Nucleic Acid Drug Dev; 1998 Apr 06; 8(2):115-22. PubMed ID: 9593049
    [No Abstract] [Full Text] [Related]

  • 7. Crohn's trial shows the pros of antisense.
    Robertson D.
    Nat Biotechnol; 1997 Mar 06; 15(3):209. PubMed ID: 9062911
    [No Abstract] [Full Text] [Related]

  • 8. ISIS 2302. INXC ICAM1, Oligo-TCS.
    Drugs R D; 1999 Jan 06; 1(1):85-6. PubMed ID: 10565996
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Antisense oligonucleotides in lung cancer.
    Pujol JL, Jacot W.
    Suppl Tumori; 2002 Jan 06; 1(4):S50-1. PubMed ID: 12415820
    [No Abstract] [Full Text] [Related]

  • 13. Phase I safety and pharmacokinetic profile of an intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302).
    Glover JM, Leeds JM, Mant TG, Amin D, Kisner DL, Zuckerman JE, Geary RS, Levin AA, Shanahan WR.
    J Pharmacol Exp Ther; 1997 Sep 06; 282(3):1173-80. PubMed ID: 9316823
    [Abstract] [Full Text] [Related]

  • 14. Antisense phosphorothioate oligodeoxyribonucleotide targeted against ICAM-1: synthetic and biological characterization of a process-related impurity formed during oligonucleotide synthesis.
    Ravikumar VT, Capaldi DC, Lima WF, Lesnik E, Turney B, Cole DL.
    Bioorg Med Chem; 2003 Oct 15; 11(21):4673-9. PubMed ID: 14527564
    [Abstract] [Full Text] [Related]

  • 15. Application of antisense oligodeoxynucleotides for organ transplantation.
    Stepkowski SM.
    Transplant Proc; 1998 Aug 15; 30(5):2142-5. PubMed ID: 9723420
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Protection against allograft rejection with intercellular adhesion molecule-1 antisense oligodeoxynucleotides.
    Stepkowski SM, Wang ME, Condon TP, Cheng-Flournoy S, Stecker K, Graham M, Qu X, Tian L, Chen W, Kahan BD, Bennett CF.
    Transplantation; 1998 Sep 27; 66(6):699-707. PubMed ID: 9771832
    [Abstract] [Full Text] [Related]

  • 18. Antisense therapeutics.
    Agrawal S, Zhao Q.
    Curr Opin Chem Biol; 1998 Aug 27; 2(4):519-28. PubMed ID: 9736926
    [Abstract] [Full Text] [Related]

  • 19. Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease.
    Yacyshyn BR, Chey WY, Goff J, Salzberg B, Baerg R, Buchman AL, Tami J, Yu R, Gibiansky E, Shanahan WR, ISIS 2302-CS9 Investigators.
    Gut; 2002 Jul 27; 51(1):30-6. PubMed ID: 12077088
    [Abstract] [Full Text] [Related]

  • 20. Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides.
    Geary RS, Leeds JM, Henry SP, Monteith DK, Levin AA.
    Anticancer Drug Des; 1997 Jul 27; 12(5):383-93. PubMed ID: 9236854
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.